Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from BeiGene

BeOne Medicines Stock Gains Momentum With Early-Stage Trial Success For Pretreated Lymphoma Patients

BeOne Medicines Ltd. (NASDAQ:ONC) (formerly BeiGene) on Friday released topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, an investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy.

Benzinga

A Glimpse Into The Expert Outlook On BeiGene Through 4 Analysts

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on BeiGene (NASDAQ:BGNE) in the last three months.

Benzinga

Why Is BeiGene Stock Trading Higher On Wednesday?

BeiGene's Tevimbra receives EU approval for advanced ESCC and G/GEJ cancers, showing significant survival benefits in pivotal Phase 3 trials.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022

Upgrades

Benzinga

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Merck's (NYSE:MRK) lead asset MK-2060 for the reduction in risk of major thrombotic cardiovascular events in patients with end-stage renal disease (ESRD). Merck shares traded in a range of $89.72 to $90.97 on day volume of 5.2…

Benzinga

Recap of Tuesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Relmada Therapeutics’ (NASDAQ:RLMD) lead asset REL-1017 as a monotherapy for the treatment major depressive disorder (MDD). Relmada shares traded in a range of $26.02 to $27.96 on a day volume of 173.79 thousand shares, closed regular trading…

Benzinga

Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas

Key takeaways: Innovent Biologics terminated a plan to sell its bevacizumab biosimilar in North America with a local partner after trials for the drug fell behind schedule The company’s loss tripled last year on growing competition for its core product, whose sales fell 22% in this year’s first-quarter

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Where BeiGene Stands With Analysts

Within the last quarter, BeiGene (NASDAQ:BGNE) has observed the following analyst ratings:

Benzinga

Recap: BeiGene Q1 Earnings

BeiGene (NASDAQ:BGNE) reported its Q1 earnings results on Thursday, May 5, 2022. Here's what investors need to know about the announcement. Earnings BeiGene beat estimated earnings by 10.36%, reporting an EPS of $-4.24 versus an estimate of $-4.73.

Benzinga

InnoCare Pharma Goes Back to Funding Trough With STAR Market Listing

Key Takeaways:

Benzinga

BeiGene's Brukinsa Tops JNJ's Imbruvica In Overall Response Rate In Leukemia Study

BeiGene Ltd (NASDAQ: BGNE) has announced results from the Phase 3 ALPINE trial of Brukinsa (zanubrutinib) in relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Benzinga

Cancer Drug Maker BeiGene Takes Action to Mitigate Delisting Risk

Key Takeaways: BeiGene has switched auditors for its New York listing to a U.S. company from a Chinese one in a move to comply with U.S. law The change could reduce the company’s threat of being forcibly delisted from the Nasdaq By Doug Young

Benzinga

Most Chinese Biotech Stocks Can Continue US Listing After New Audit Framework

According to a Bloomberg report, U.S. regulators could reportedly have full access to auditing reports from most of the 200-plus China-based companies listed in New York in mid-2022. In the drafting stage, the framework from the China Securities Regulatory Commission and other national agencies would let most Chinese firms keep their U.S.…

Benzinga

Analyst Ratings For BeiGene

Over the past 3 months, 4 analysts have published their opinion on BeiGene (NASDAQ:BGNE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

The Daily Biotech Pulse: Valneva Gains On COVID Shot Regulatory Update, Lucira Health And Clearside Jump On Earnings, BeiGene Drug Snags Approval In China

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

BeiGene: Q4 Earnings Insights

BeiGene (NASDAQ:BGNE) reported its Q4 earnings results on Friday, February 25, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga

BeiGene's Brukinsa Applications Under FDA, European Review For Leukemia

The

People

Doug Young

39 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.